Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
18 hedge funds and large institutions have $17.7M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 6 closing their positions.
22% less funds holding
Funds holding: 23 → 18 (-5)
56% less capital invested
Capital invested by funds: $40.2M → $17.7M (-$22.5M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$91.8K |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$9.96K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$996 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kryger Capital
London,
United Kingdom
|
-$3.86M |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$3.51M |
| 3 |
CCM
Context Capital Management
Lajolla,
California
|
-$1.15M |
| 4 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
-$271K |
| 5 |
WC
Wealthspring Capital
West Harrison,
New York
|
-$201K |
IBER.U Hedge Fund Activity: Q1 2022 in Review
18 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q1 2022, worth a combined $17.7M — down 56% from $40.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IBER.U and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Wolverine Asset Management, adding an estimated $91.8K. The largest seller was Kryger Capital, exiting entirely with an estimated $3.86M sold.
- 18 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q1 2022, down from 23 in Q4 2021.
- Funds reported $17.7M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q1 2022, down 56% quarter-over-quarter.
- 2 funds opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q1 2022 and 6 closed out, a net change of -4 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q1 2022 was Wolverine Asset Management, an estimated $91.8K added.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q1 2022 was Kryger Capital, an estimated $3.86M sold.
Based on aggregated 13F filings for Q1 2022.